 This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The Complaint alleges that throughout the Class Period, Defendants made materially false andor misleading statements that: 1 important data from the Companys Phase 2a trial in atopic dermatitis, including the timing and extent of patients use of topical corticosteroids as a rescue therapy during the study and whether any of the patients that utilized rescue therapy were classified as responders at a given time; 2 key information from the Companys Phase 2a trial in peanut allergy, including patients average cumulative peanut dose tolerated at day 14 after the administration of etokimab or placebo as well as whether the Companys decision to exclude 20 of the patients enrolled in the study from the interim analysis due to their mild symptoms was retrospective; and 3 as a result, Defendants positive statements about the efficacy and prospects of AnaptysBios lead drug asset, etokimab formerly ANB020, in the treatment of atopic dermatitis and peanut allergy were materially false andor misleading andor lacked a reasonable basis. 